Chemical formula: C₅FeN₆O Molecular mass: 215.938 g/mol PubChem compound: 11963622
The principal pharmacological action of nitroprusside is relaxation of vascular smooth muscle and consequent dilation of peripheral arteries and veins. Other smooth muscle (e.g. uterus, duodenum) is not affected. Nitroprusside is more active on veins than on arteries.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C02DD01 | Nitroprusside | C Cardiovascular system → C02 Antihypertensives → C02D Arteriolar smooth muscle, agents acting on → C02DD Nitroferricyanide derivatives |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| DBL SODIUM NITROPRUSSIDE Solution for injection | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC | |
| NIPRIDE RTU Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Nitroprusside is an active ingredient of these brands:
United States (US)Austria (AT)Canada (CA)Finland (FI)Hong Kong (HK)Israel (IL)Japan (JP)South Africa (ZA)Turkey (TR)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
